Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions.
Toll Like Receptors Signaling Pathways as a Target for Therapeutic Interventions.
复制标题
DOI：
10.2174/157436211797483930
复制
发表时间：
2011
影响因子：
--
通讯作者：
Verin AD
中科院分区：
文献类型：
--
作者：
Jezierska A;Kolosova IA;Verin AD
本文综述了Toll样受体（TLR）分子在免疫系统中的关键作用。TLR被广泛的病原体、细胞因子或其他特异性分子激活，触发先天性免疫应答。已发表的数据表明，用特定抑制剂靶向和抑制TLR和TLR相关蛋白可为患有癌症、哮喘、败血症、克罗恩病和血栓形成的患者提供关键治疗。许多靶向细胞因子的药物在活化途径的后期起作用，在细胞环境中形成最终的肽、蛋白质或糖蛋白之后。TLR活性发生在细胞通路的早期激活中;因此抑制它们可能在人类疾病的治疗中最有益。
This review summarizes the key role of Toll-Like Receptor (TLRs) molecules for igniting the immune system. Activated by a broad spectrum of pathogens, cytokines or other specific molecules, TLRs trigger innate immune responses. Published data demonstrate that the targeting and suppression of TLRs and TLR-related proteins with particular inhibitors may provide pivotal treatments for patients with cancer, asthma, sepsis, Crohn's disease and thrombosis. Many drugs that target cytokines act in the late phases of the activated pathways, after the final peptides, proteins or glycoproteins are formed in the cell environment. TLR activity occurs in the early activation of cellular pathways; consequently inhibiting them might be most beneficial in the treatment of human diseases.